Pacer Advisors Inc. Grows Holdings in Dynavax Technologies Corporation $DVAX

Pacer Advisors Inc. grew its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 3,639.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 322,119 shares of the biopharmaceutical company’s stock after purchasing an additional 313,506 shares during the period. Pacer Advisors Inc. owned approximately 0.27% of Dynavax Technologies worth $3,199,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Osaic Holdings Inc. grew its holdings in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares in the last quarter. Callan Family Office LLC acquired a new position in shares of Dynavax Technologies in the second quarter worth $107,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Dynavax Technologies during the second quarter worth $121,000. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Dynavax Technologies during the second quarter worth $127,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of Dynavax Technologies in the second quarter valued at $136,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Insiders Place Their Bets

In other news, COO David F. Novack sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the completion of the sale, the chief operating officer owned 111,451 shares in the company, valued at approximately $1,726,375.99. The trade was a 21.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $15.37 on Wednesday. The business has a 50-day moving average of $11.31 and a two-hundred day moving average of $10.65. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -41.54 and a beta of 0.89. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $15.49. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. On average, analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.